Sön 4 dec / År 40 / Nr 5 2022

Neoventa’s fetal monitoring to be implemented across broad markets

Swedish medical technology is widely regarded as one of the world’s most prominent in terms of research and development. Many of today’s global standards within the medical business and healthcare have been developed in line with Swedish innovations. After several successful studies in the field of perinatal healthcare and medicine, Swedish-based Neoventa Medical AB has developed a revolutionary medical device monitoring the fetal heart.

Neoventa Medical AB, headquartered in Mölndal just outside Göteborg, was established in 1997. The company has developed monitoring and management tools for improved perinatal healthcare. By combining a unique medical expertise with digital signal processing technology to establish ST analysis of the fetal heart, Neoventa has launched one of the most exciting advances within the field of perinatal medicine. STAN S31 is the latest of a series of products for this purpose.

Focus on technology
The feature option ST Analysis is based on changes in the fetal ECG waveform and provides additional information of the fetus condition during labour as an adjunct to the recording of the FHR. The unique combination of ST Analysis and CTG provides more accurate information about the fetus and helps medical staff identify risks due to oxygen deficiency.

Significantly improved results
Of Neoventa’s total produce, a generous 90 per cent is exported to hospitals all over the world, with a strong position in Scandinavia and Europe. The method generates significantly improved results as the information-flow is consistent during the entire labour process. “This is yet another example of Swedish expertise and research resulting in a world-leading innovation”, states Jan Stålemark, CEO of Neoventa Medical. “The STAN system is developed onto a most flexible platform which provides numerous feature options to guarantee the best possible solution for fetal and maternal monitoring needs”.

Reduces asphyxia by more than 90 per cent
A large Swedish clinical study has recently been published in the acclaimed American Journal of Obstetrics and Gynecology. The study is unique and summarises all deliveries at one hospital over a seven year period. The results show that since the introduction of the STAN monitor with ST Analysis, the number of babies born with asphyxia during birth has been reduced by more than 90 per cent. “Independent studies have shown the same results. The method reduces asphyxia and therefore also the risk for brain and organ damage for the baby”, exclaims Stålemark.

NIH conducts largest study in history
The FDA has recently approved STAN in the USA and the introduction of the STAN method there is ongoing. The National Institute of Health (NIH) will now conduct the largest study in history in the area of medical devices of this sort. As the world economy stabilises the demand for Neoventa’s innovation will increase. “Swedish and European study results have been consistent over the years. After NIH have presented their findings we are looking forward to a wide establishment across the USA”, Stålemark concludes.

Maria Lind